By Chris Cummings, Senior Business Development Manager, LSN
With just over seven weeks to go RESI Boston, LSN is getting ready to assess which health innovators will be awarded a display spot in our NIH-sponsored RESI Innovation Challenge. If you would like to participate and get an exhibit hall display spot to market your company to life science investors, it’s not too late to apply.
The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants will be vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.
On September 26th, RESI’s estimated 1000 attendees will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership. See below for the previous RESI Innovation Challenge first place winners – a diverse group of startups from every area of the life sciences.
- Taithera (New York, NY) – Therapeutics
- Steadiwear (Toronto, ON) – Medical Device
- Pathcore (Toronto, ON) – Healthcare IT
- BioMedomics (Durham, NC, USA) – Diagnostics
- Perimeter(Toronto, ON) – Diagnostics
- GeneSegues Therapeutics(Chaska, MN) – Therapeutics
- Clearsight(Aurora, CO) – Medical Device
- Rna Diagnostics(Toronto, ON) – Diagnostics
- Redox(Madison, WI) – Healthcare IT
- Empiriko(Newton, MA) – Therapeutics
- ORIG3N(Boston, MA) – Service Provider
- Kineta(Seattle, WA) – Therapeutics
Michael Quigley, VP of Market Research, Life Science Nation | Mo Chen, Co-Founder & Chief Science Officer, Taithera | Seth Harlem, Co-Founder & Chief Executive Officer, Taithera
See below for the previous RESI Innovation Challenge testimonials.
“RESI Innovation Challenge was a fantastic way for us to increase exposure to investors attending the event. We highly recommend leveraging the Innovation Challenge with the one-on-one partnering platform to get more face time with investors.”
– Herman Lo, CEO, ViewsIQ Inc.
3rd Place in San Diego IC
“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016
“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space. It’s a good showcase to reach that audience.”
– Jessica Ching, CEO, Eve Medical
2nd Place, RESI San Francisco, January 12, 2016
“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”
– John Connolly, VP Corporate Development, Rna Diagnostics
1st Place, RESI Boston, September 16, 2015
LSN is pleased to announce WuXi AppTec will be a title sponsor to the RESI Conference Series in our upcoming Boston, NYC and San Francisco conferences. WuXi AppTec is a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform. WuXi AppTec joins RESI as a title sponsor along with JLABS, which currently has eight locations in innovation hotspots across North America and produces entrepreneurial programs and campaigns to seek out the best science. This pair of global early stage players will add another conduit to the early stage companies that come to RESI to find investor capital and strategic partnerships as they move forward in their product cycles.
